Believes New Independent Directors Are Needed to Correct the Board’s Misaligned Priorities and Prevent Further Value Destruction
Reveals Seer’s Board Has Not Responded to the Radoff-JEC Group’s Stockholder-Friendly Offer Made on June 15 to Resolve the Ongoing Proxy Contest, Demonstrating the Board's Focus on its Own Entrenchment
HOUSTON -- (Business Wire)
Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624630276/en/

Source: FactSet, Company proxy statements. Graph and figures are from December 4, 2020 through December 31, 2025.
- Seer’s Board of Directors (the “Board”) has destroyed value for stockholders while enriching Company insiders:
-
The Company has posted a -97.0% share price decline since its December 2020 IPO.1
-
Seer has generated cumulative reported losses exceeding $465 million since its IPO.2
-
Seer has delivered virtually no revenue growth over the last three fiscal years, while investing over $160 million.3
-
The Board has rewarded Chairman and CEO Omid Farokhzad, M.D. with nearly $37 million in cumulative compensation while a stockholder who purchased one share at the time of the IPO ($19.00) would be left with less than $0.63.4
- Seer has no plan to create stockholder value under Chairman and CEO Omid Farokhzad, M.D.:
-
Dr. Farokhzad has destroyed more than $1 billion in investor capital across five separate companies, evidence supporting our belief that he is incapable of turning around Seer.5
-
The strategic plan overseen by the Board anticipates Seer will not achieve profitability until 2031.6
-
The Board rejected our three proposals to acquire Seer for premiums of 33% - 42% to its unaffected share price and a contingent value right – proposals which we believe provide substantially greater certainty of value creation than the Company’s current strategic plan – without even engaging with us.
- Seer’s Board has not responded to our proposal to settle this proxy contest:
-
On June 15, 2026, we proposed to end our ongoing proxy contest in exchange for Seer adopting governance enhancements and conducting a tender offer for 20 million shares at $2.50 per share, which would be in line with the Board’s authorized buyback program and management’s statements that there is a “significant dislocation” in the Company’s share price.7
-
More than a week later, the Board has still not responded to our settlement offer – which it requested in the first place – demonstrating that its priority is not delivering value or governance improvements for stockholders.
-
Instead of focusing on opportunities to maximize value for stockholders as Seer’s share price has consistently traded at a significant discount to net cash, the Board has diluted stockholders by repeatedly issuing large grants of restricted stock units and in-the-money options to Dr. Farokhzad and President and CFO David Horn.
Vote FOR the Radoff-JEC Group’s Nominees – Howard H. Berman, Ph.D., Joshua S. Horowitz and Luis E. Rinaldini – Today to Prevent Further Value Destruction
Do NOT Vote for Omid Farokhzad, M.D., Terrance McGuire or Dipchand (Deep) Nishar
Questions about how to vote? Contact (888) 368-0379 or info@saratogaproxy.com.
Visit www.SaratogaProxy.com/SEER to learn more.
| _________________________________________ |
1FactSet. Share price decline from December 4, 2020 through April 10, 2026, the trading day immediately prior to the Radoff-JEC Group’s submission of its initial proposal to acquire the Company.
|
2 The Company’s Form 10-K for the year ended December 31, 2025 filed on March 2, 2026.
|
3 Company Form 10-K filings.
|
4 Company proxy statements. FactSet; share price decline from December 4, 2020 through December 31, 2025.
|
5 Seer, BIND Therapeutics, Inc., Selecta Biosciences, Inc., Tarveda Therapeutics, Inc. and Senti Biosciences Holdings, Inc.
|
6 Company PRE 14A filed on October 10, 2025.
|
7 On the Company’s Q1 2026 earnings call held on May 13, 2026, President and CFO David Horn said: “Our opportunistic share repurchase in the quarter reflect our continued belief that there is a significant dislocation in our share price.”
|

View source version on businesswire.com: https://www.businesswire.com/news/home/20260624630276/en/
Contacts:
Greg Lempel
greg@fondrenlp.com
or
Saratoga Proxy Consulting LLC
John Ferguson / Joseph Mills, 212-257-1311
info@saratogaproxy.com
Source: On Behalf of The Radoff-JEC Group
© 2026 Canjex Publishing Ltd. All rights reserved.